Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Merck To Join Pfizer and Lilly At Top of DoJ Settlements Chart

  • News

Executive Summary

Merck is set to reach the third largest settlement with the Department of Justice involving drug marketing practices.

You may also be interested in...



Vioxx Settlement Down, Merck Has Three More Government Probes Pending

Sales rep call notes on Vioxx off-label promotion were a key part of the government’s criminal case against Merck; $950 million settlement includes a new corporate integrity agreement that requires monitoring of call notes.

Merck’s Morass Of Marketing Probes: DoJ Seeks Data On Three More Drugs

Department of Justice has requested data on AzaSite, which Merck gained in its acquisition of Inspire Pharmaceuticals, Integrilin and Avelox.

No End In Sight: Pharma Companies Continue To Face Government Probes

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

EMA To Explain How Trial Transparency & Data Redaction Can Live Together

Pink Sheet Podcast: Big Pharma’s US FDA Scorecard, Sarepta’s DMD Gene Therapy Delay, US FDA Adcomm Reforms

Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else

US FDA Complete Response Letter Rates Vary With Sponsor Size

See All
UsernamePublicRestriction

Register

PS052813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By